Prognostic Significance of Circulating Melanoma Cells in High-Risk Patients
Author Information
Author(s): Gogas H, Kefala G, Bafaloukos D, Frangia K, Polyzos A, Pectasides D, Tsoutsos D, Panagiotou P, Ioannovich J, Loukopoulos D
Primary Institution: University of Athens
Hypothesis
The presence of circulating melanoma cells detected by RT–PCR is a prognostic marker for relapse in high-risk melanoma patients receiving adjuvant interferon.
Conclusion
Circulating melanoma cells are markers of a high relapse risk and shorter disease-free survival in melanoma patients.
Supporting Evidence
- Tyrosinase mRNA was detected in 70% of patients, correlating with shorter disease-free survival.
- Patients who tested negative for tyrosinase mRNA had a significantly lower probability of recurrence.
- The median disease-free survival was 21 months for the RT–PCR positive group.
Takeaway
This study found that if melanoma cells are detected in the blood, it means a higher chance of the disease coming back.
Methodology
The study analyzed blood samples for tyrosinase mRNA using RT–PCR at multiple time points in melanoma patients undergoing treatment.
Potential Biases
Potential biases may arise from the lack of randomization and the specific treatment protocol used.
Limitations
The study did not include untreated patients for comparison and may not be generalizable to all stage II and III melanoma patients.
Participant Demographics
Patients were stage IIB and III melanoma patients, with a median follow-up of 23 months.
Statistical Information
P-Value
0.03
Confidence Interval
95% CI 17.4–28.6
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website